Market Size
The global pneumothorax treatment market was valued at USD 1.48 billion in 2025 and is projected to reach nearly USD 2.36 billion by 2033, growing at a CAGR of 6.8% during the forecast period from 2026 to 2033.
The market is witnessing steady growth driven by the increasing incidence of spontaneous and traumatic pneumothorax cases, rising prevalence of chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma, and growing demand for minimally invasive thoracic treatment procedures. Expanding adoption of advanced chest drainage systems, pleural catheters, thoracic surgery technologies, and video assisted thoracoscopic surgery (VATS) procedures is significantly supporting market expansion globally. In addition, improvements in emergency care infrastructure, increasing trauma cases, and advancements in portable digital drainage systems are enhancing treatment efficiency and patient outcomes across healthcare facilities.
Pneumothorax Treatment Market Dynamics
Advancement in the diagnosis of pneumothorax is expected to drive market growth.
Chest radiography is one of the most cost-effective and widely available diagnostic methods for detecting various chest diseases, including pneumothorax. The researchers are inspired to contribute to the automation of the diagnostic process using chest radiographs by the success of deep learning techniques in other domains of medicine. As a result, various frameworks for automatic pneumothorax detection have been presented, leveraging various machine learning and, in particular, deep learning techniques. Therefore, the current best-performing model for the NIH Chest Xray14 dataset was provided by Baltruschat. Thus, the market is expected to drive in the forecast period from the above statements.
Restraint:
Lack of awareness regarding pneumothorax infections in emerging countries delayed diagnosis and a low incidence of diagnosis, and fewer side effects caused by the drugs are some of the factors the market is expected to hamper the market growth.
Pneumothorax Treatment Market Segment Analysis
Opiate Analgesics segment is expected to hold the largest market share in pneumothorax treatment market
The opiate analgesics segment is expected to dominate in 2020. The segment benefits because pain control with opiate analgesics is vital for appropriate patient care since it ensures patient comfort and facilitates the pulmonary toilet. Most analgesics contain sedative qualities, which might help patients with painful skin lesions. These medications are necessary for the initial installation of thoracostomy tubes and pain management following the procedure. For instance, Fentanyl citrate (Sublimaze), The onset of analgesia with fentanyl citrate is immediate when administered intravenously (IV), and the analgesia lasts 30-60 minutes. The respiratory depressive effect, on the other hand, may continue longer than analgesia. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Pneumothorax Treatment Market Scope
| Metrics | Details |
| Market CAGR | 6.8% |
| Segments Covered | By Medication, By Treatment Type, By Indication, By End-User, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Pneumothorax Treatment Market Geographical Analysis
North America region holds the largest market share in the global pneumothorax treatment market
In 2025, North America accounted for the highest revenue share. The increasing prevalence of the pneumothorax infection, advancement in diagnosis procedures and FDA Clearance to the market players, is some factors the market is expected to boost in the forecast period. For instance, according to the National Center for Biotechnology Information, Primary spontaneous pneumothorax is most common in people between 20 and 30. PSP affects 7 per 100,000 men and 1 per 100,000 women in the United States each year. Recurrence occurs in most cases within the first year, with rates ranging from 25% to 50%. The first 30 days have the highest recurrence rate.
Moreover, Patients in their 60s and 65s are more likely to develop secondary spontaneous pneumothorax. For men and women, the incidence of SSP is 6.3 and 2 incidences per 100,000 patients, respectively. The ratio of males to females is 3:1. The number of pneumothoraxes per 100,000 people with COPD is 26. Heavy smokers had a 102-fold higher risk of spontaneous pneumothorax than non-smokers. Additionally, On September 13, 2019, The US Food and Drug Administration (FDA) granted 510(k) clearance to GE Healthcare’s artificial intelligence (AI) algorithms, Critical Care Suite, to identify pneumothorax, a type of collapsed lung. Therefore, it has increased the demand for the treatment of pneumothorax, due to which the North American region is expected to hold the largest market share in the forecast period.
Key Developments
February 2026: Rising adoption of minimally invasive thoracic drainage procedures across North America and Europe improved treatment outcomes and reduced hospitalization duration for pneumothorax patients. Major companies including Medtronic, Teleflex Incorporated, and Smiths Medical expanded advanced chest drainage and thoracic vent device portfolios.
January 2026: Increasing investments in emergency and critical care infrastructure across the United States, Germany, Japan, and China accelerated demand for advanced pneumothorax treatment devices and thoracic drainage systems. Healthcare providers focused on portable and AI-assisted monitoring technologies supporting real-time pleural pressure management.
December 2025: Growing prevalence of respiratory disorders, chest trauma, and post-surgical pneumothorax cases across Asia-Pacific strengthened adoption of minimally invasive catheter insertion and chest tube procedures. Abbott Laboratories and Vygon strengthened regional distribution networks and respiratory care technologies.
November 2025: Expansion of ambulatory surgical centers and trauma care facilities across Europe and North America increased utilization of compact thoracic vent devices and portable chest drainage systems. Hospitals increasingly focused on improving patient mobility and reducing procedure-related complications through advanced drainage technologies.
October 2025: Rising advancements in AI-enabled chest X-ray analysis and automated pneumothorax detection technologies improved diagnostic accuracy and emergency treatment planning globally. Research institutions in the United States developed deep-learning segmentation models supporting faster pneumothorax identification and radiology workflow optimization.
September 2025: Increasing collaborations between medical device manufacturers and healthcare institutions accelerated development of next-generation thoracic drainage systems with enhanced portability and safety features. Cook Medical and B. Braun Melsungen AG strengthened innovation strategies targeting minimally invasive respiratory care applications.
August 2025: Growing healthcare infrastructure modernization across India, Southeast Asia, and Middle East regions accelerated installation of advanced respiratory care and emergency treatment systems. Asia-Pacific emerged as the fastest growing regional market driven by increasing respiratory disease burden and expanding healthcare expenditure.
July 2025: Rising focus on portable and home-based respiratory monitoring technologies improved adoption of compact pneumothorax treatment devices across outpatient and ambulatory care settings globally. Companies explored digital monitoring solutions supporting remote patient management and real-time air leak assessment.
June 2025: Increasing government support for emergency healthcare infrastructure and growing awareness regarding early pneumothorax diagnosis supported strong growth in the global pneumothorax treatment market. North America maintained market leadership, while Asia-Pacific emerged as the fastest growing regional market due to rising trauma cases and healthcare investments.
Pneumothorax Treatment Market Competitive Landscape
Major key players in the pneumothorax treatment market are Pfizer Inc., Fresenius Kabi USA, Akorn, Inc., Piramal Critical Care, Baxter Healthcare Corporation, Valeant Pharmaceuticals North America LLC, Teva Pharmaceuticals USA, Inc., Comed Chemicals Ltd., UCB, Inc. and Midas Pharma GmbH.
Pfizer Inc.:
Overview:
Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its medicines and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
Product Portfolio:
LIDOCAINE HYDROCHLORIDE (lidocaine hydrochloride): Lidocaine HCl stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.
